Cipla

{
  "main_header": {
    "sid": 597145,
    "name": "Cipla",
    "stock_name": "Cipla",
    "full_name": "Cipla Ltd.",
    "name_url": "stocks-analysis/cipla",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,362.85",
    "chg": -2.4,
    "chgp": "-0.18%",
    "dir": -1,
    "prev_price": "1,365.25",
    "mcapval": "110,747.00 Cr",
    "mcap": "Large Cap",
    "scripcode": 500087,
    "symbol": "CIPLA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE059A01026",
    "curr_date": "May 07",
    "curr_time": "",
    "bse_nse_vol": "12.93 lacs",
    "exc_status": "Active",
    "traded_date": "May 07, 2026",
    "traded_date_str": "2026 05 07",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/cipla-597145-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "P/E at 23.10 vs Industry's 34.48: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-amid-institutional-shifts-and-sector-dynamics-3979151",
        "imagepath": "",
        "date": "2026-05-07 09:20:44",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discounted P/E Amid Sector Premium</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> trades at a P/E multiple of 23.10, substantially below the Pharmaceuticals &amp; Biotechnology industry average of 34.48. This 33% discount suggests the market is pricing in either subdued growth expectations or risk factors not reflected in the broader sector valuation. The sector’s elevated P/E is supported by strong earnings growth and positive results from all seven companies that have declared so far this season, with zero flat or negative outcomes. This contrast raises the question of whether <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> is un..."
      },
      {
        "title": "P/E at 22.66 vs Industry's 33.83: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-amidst-mixed-performance-and-institutional-shifts-3977231",
        "imagepath": "",
        "date": "2026-05-06 09:20:51",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amid Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> trades at a P/E multiple of 22.66, markedly below the Pharmaceuticals &amp; Biotechnology industry average of 33.83. This 33% discount to sector valuation suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. Such a valuation gap is notable given the sector’s overall positive earnings momentum, with all six companies reporting results so far posting positive outcomes. The discount raises the question of whether <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> is undervalued or facing structural challenges ..."
      },
      {
        "title": "P/E at 22.68 vs Industry's 33.77: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-challenges-amidst-nifty-50-membership-and-institutional-shifts-3975386",
        "imagepath": "",
        "date": "2026-05-05 09:20:37",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discounted P/E Amid Sector Premiums</strong></p>\n                <p>The current P/E ratio of 22.68 for <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> stands well below the sector average of 33.77, indicating a substantial valuation discount. This divergence suggests the market is pricing in either company-specific challenges or a cautious outlook relative to peers. The sector’s elevated P/E reflects strong earnings growth expectations, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla</a> appears to be lagging in investor confidence despite its large-cap status and ₹1,07,673.39 crore market capitalisation. <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-59714..."
      },
      {
        "title": "P/E at 22.3 vs Industry's 33.4: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-challenges-amidst-nifty-50-membership-and-institutional-shifts-3973315",
        "imagepath": "",
        "date": "2026-05-04 10:30:31",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> currently trades at a P/E of 22.3, markedly below the Pharmaceuticals &amp; Biotechnology industry average of 33.4. This 33% discount to sector valuation suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. Such a gap is notable given the sector’s overall positive earnings momentum, with all three companies reporting results so far posting positive outcomes. The valuation gap raises the question <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">previously rated Hold, what is Cipla Ltd.'s current rating?</a> The premium..."
      },
      {
        "title": "P/E at 22.27 vs Industry's 33.42: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-amidst-mixed-performance-and-institutional-shifts-3969650",
        "imagepath": "",
        "date": "2026-04-30 09:20:39",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> trades at a P/E multiple of 22.27, markedly below the Pharmaceuticals &amp; Biotechnology sector average of 33.42. This 33% discount to the industry multiple indicates that the market currently values the company’s earnings more conservatively than its peers. Such a valuation gap often reflects concerns about growth prospects, profitability sustainability, or sector-specific headwinds. However, it also raises the question of whether the stock is undervalued relative to its fundamentals — <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"ctx\">previously rated Hold, what is Cip..."
      },
      {
        "title": "P/E at 22.26 vs Industry's 33.32: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-challenges-amidst-nifty-50-membership-and-sector-dynamics-3967721",
        "imagepath": "",
        "date": "2026-04-29 09:20:40",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E of <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> at 22.26 stands well below the industry average of 33.32, reflecting a valuation discount of approximately 33%. This divergence may imply that the market is pricing in concerns about growth or profitability relative to sector peers. The Pharmaceuticals & Biotechnology sector often commands premium valuations due to innovation pipelines and defensive characteristics, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> appears to be trading at a more conservative multiple. <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145..."
      },
      {
        "title": "Cipla Ltd. is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/cipla-ltd-is-rated-sell-by-marketsmojo-3966407",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/CiplaLtd_mojoScore_3966407.png",
        "date": "2026-04-28 10:10:39",
        "description": "Cipla Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "P/E at 22.35 vs Industry's 33.33: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-amid-institutional-shifts-and-market-dynamics-3966020",
        "imagepath": "",
        "date": "2026-04-28 09:20:36",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> trades at a P/E multiple of 22.35, considerably below the Pharmaceuticals &amp; Biotechnology industry average of 33.33. This 33% discount to sector valuation suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. The sector’s elevated P/E reflects optimism around innovation and pipeline potential, but <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla</a> appears to be viewed more conservatively. Investors might wonder <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"ctx\">previously rated..."
      },
      {
        "title": "Cipla Ltd. Sees Significant Open Interest Surge Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-sees-significant-open-interest-surge-amid-mixed-market-signals-3964664",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/CiplaLtd_oi_spurts_by_underlying_3964664.png",
        "date": "2026-04-27 15:00:22",
        "description": "Cipla Ltd., a leading player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 13.44% surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this, the stock underperformed its sector peers on 27 Apr 2026, reflecting a complex interplay of bullish and bearish sentiments among traders."
      }
    ],
    "total": 1030,
    "sid": "597145",
    "stock_news_url": "https://www.marketsmojo.com/news/cipla-597145"
  },
  "announcements": [
    {
      "caption": "Cipla Receives U.S. FDA Approval For First AB Rated Generic Of Ventolin® HFA",
      "datetime": "23-Apr-2026",
      "details": "Please find enclosed intimation",
      "source": "BSE"
    },
    {
      "caption": "USFDA Inspection At CompanyS Manufacturing Facility In Goa India",
      "datetime": "17-Apr-2026",
      "details": "USFDA inspection at Companys manufacturing facility in Goa India",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "16-Apr-2026",
      "details": "We are enclosing herewith earnings call intimation scheduled to be held on 13th May 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "13 May 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Cipla Ltd. has declared <strong>650%</strong> dividend, ex-date: 27 Jun 25",
          "dt": "2025-06-27",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Cipla Ltd. has announced <strong>3:2</strong> bonus issue, ex-date: 24 Apr 06",
          "dt": "2006-04-24",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

P/E at 23.10 vs Industry's 34.48: What the Data Shows for Cipla Ltd.

2026-05-07 09:20:44

Valuation Picture: Discounted P/E Amid Sector Premium

Cipla Ltd. trades at a P/E multiple of 23.10, substantially below the Pharmaceuticals & Biotechnology industry average of 34.48. This 33% discount suggests the market is pricing in either subdued growth expectations or risk factors not reflected in the broader sector valuation. The sector’s elevated P/E is supported by strong earnings growth and positive results from all seven companies that have declared so far this season, with zero flat or negative outcomes. This contrast raises the question of whether Cipla Ltd. is un...

Read full news article

P/E at 22.66 vs Industry's 33.83: What the Data Shows for Cipla Ltd.

2026-05-06 09:20:51

Valuation Picture: Discount Amid Sector Premiums

Cipla Ltd. trades at a P/E multiple of 22.66, markedly below the Pharmaceuticals & Biotechnology industry average of 33.83. This 33% discount to sector valuation suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. Such a valuation gap is notable given the sector’s overall positive earnings momentum, with all six companies reporting results so far posting positive outcomes. The discount raises the question of whether Cipla Ltd. is undervalued or facing structural challenges ...

Read full news article

P/E at 22.68 vs Industry's 33.77: What the Data Shows for Cipla Ltd.

2026-05-05 09:20:37

Valuation Picture: Discounted P/E Amid Sector Premiums

The current P/E ratio of 22.68 for Cipla Ltd. stands well below the sector average of 33.77, indicating a substantial valuation discount. This divergence suggests the market is pricing in either company-specific challenges or a cautious outlook relative to peers. The sector’s elevated P/E reflects strong earnings growth expectations, yet Cipla appears to be lagging in investor confidence despite its large-cap status and ₹1,07,673.39 crore market capitalisation. Read full news article

P/E at 22.3 vs Industry's 33.4: What the Data Shows for Cipla Ltd.

2026-05-04 10:30:31

Valuation Picture: Discount Amidst Sector Premiums

Cipla Ltd. currently trades at a P/E of 22.3, markedly below the Pharmaceuticals & Biotechnology industry average of 33.4. This 33% discount to sector valuation suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. Such a gap is notable given the sector’s overall positive earnings momentum, with all three companies reporting results so far posting positive outcomes. The valuation gap raises the question previously rated Hold, what is Cipla Ltd.'s current rating? The premium...

Read full news article

P/E at 22.27 vs Industry's 33.42: What the Data Shows for Cipla Ltd.

2026-04-30 09:20:39

Valuation Picture: Discount Amidst Sector Premiums

Cipla Ltd. trades at a P/E multiple of 22.27, markedly below the Pharmaceuticals & Biotechnology sector average of 33.42. This 33% discount to the industry multiple indicates that the market currently values the company’s earnings more conservatively than its peers. Such a valuation gap often reflects concerns about growth prospects, profitability sustainability, or sector-specific headwinds. However, it also raises the question of whether the stock is undervalued relative to its fundamentals — previously rated Hold, what is Cip...

Read full news article

P/E at 22.26 vs Industry's 33.32: What the Data Shows for Cipla Ltd.

2026-04-29 09:20:40

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of Cipla Ltd. at 22.26 stands well below the industry average of 33.32, reflecting a valuation discount of approximately 33%. This divergence may imply that the market is pricing in concerns about growth or profitability relative to sector peers. The Pharmaceuticals & Biotechnology sector often commands premium valuations due to innovation pipelines and defensive characteristics, yet Cipla Ltd. appears to be trading at a more conservative multiple. Read full news article

Cipla Ltd. is Rated Sell by MarketsMOJO

2026-04-28 10:10:39

Cipla Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

P/E at 22.35 vs Industry's 33.33: What the Data Shows for Cipla Ltd.

2026-04-28 09:20:36

Valuation Picture: Discount Amidst Sector Premiums

Cipla Ltd. trades at a P/E multiple of 22.35, considerably below the Pharmaceuticals & Biotechnology industry average of 33.33. This 33% discount to sector valuation suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. The sector’s elevated P/E reflects optimism around innovation and pipeline potential, but Cipla appears to be viewed more conservatively. Investors might wonder previously rated...

Read full news article

Cipla Ltd. Sees Significant Open Interest Surge Amid Mixed Market Signals

2026-04-27 15:00:22

Cipla Ltd., a leading player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 13.44% surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this, the stock underperformed its sector peers on 27 Apr 2026, reflecting a complex interplay of bullish and bearish sentiments among traders.

Read full news article

View All News